Correction to: Cancer Gene Therapy 10.1038/s41417-022-00501-1, published online 15 July 2022
In Table 2 of this article, the data in the Table 2 headed Nrf2 overexpression increases cytarabine resistance in acute myeloid leukemia through inhibition of replication factor C4 were mistakenly listed under the table 2.
Table 2.
Sample characteristics at before relapse (newly diagnosed) and relapse in the same AML patient (n = 15).
| Before relapse | Relapse | P Value | ||
|---|---|---|---|---|
| WBC (×109/L) | Median | 13.74 | 15.44 | 0.736 |
| Range | 2.11–223.39 | 0.66–185.89 | ||
| HB (×109/L) | Median | 79.00 | 94.00 | 0.580 |
| Range | 44.00–129.00 | 23.00–129.00 | ||
| PLT (×109/L) | Median | 51.00 | 24.00 | 0.623 |
| Range | 4.00–346.00 | 6.00–402.00 | ||
| RBC (×109/L) | Median | 2.25 | 2.63 | 0.415 |
| Range | 1.27–4.06 | 1.27–3.85 | ||
| BM Blast (%) | Median | 42.00 | 71.75 | 0.073 |
| Range | 21.29–93.57 | 22.06–92.14 | ||
| Gene mutation | Mutation | 4 (26.7%) | 6 (40%) | 0.456 |
| No mutation | 11 (73.4%) | 9 (60%) |
BM bone marrow, HB hemoglobin, PLT platelet and WBC white blood cell, RBC red blood cell.
We have carefully corrected this error, and the corrected Table 2 is as shown above.
The original article has been corrected.
Footnotes
The article to which this update relates has been retracted. Please see the retraction notice for more detail: 10.1038/s41417-025-00913-9
Contributor Information
Jishi Wang, Email: wangjishi9646@163.com.
Qin Fang, Email: fangqin@gmc.edu.cn.